NRC and AvidBiologics Progress New Treatments to Seek and Destroy Cancer Cells
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 10/28/14 -- Canadian company AvidBiologics Inc. and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs). Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.
Since the start of the project in early 2013, NRC''s antibody expertise has helped advance AvidBiologics'' lead treatment more rapidly. By late September 2014, the data helped convince Avid''s investors to close a new financing round. Avid will now complete confirmatory preclinical testing for its lead candidate in anticipation of its initial clinical trial in 2015, bringing this promising new treatment several steps closer to patients.
The National Research Council of Canada also developed a custom cell line needed to produce the antibody and is optimizing the parameters for its production. The goal is to transfer the cell line and bioprocess to a Canadian contract manufacturing organization to produce the clinical trial material.
Quick Facts
Quote
"Our work with leading Canadian biotech companies such as AvidBiologics shows how the National Research Council''s world-class expertise can help in the fight against cancer and improve the lives of Canadians."
Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada
"The work performed by NRC is crucial to assembling the data package needed for clinical trials. We are privileged to be able to continue the rapid development of our lead candidate while advancing the other candidates in the pipeline in collaboration with the NRC. We thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company."
Ilia A. Tikhomirov, President and CEO of Avid Biologics
Additional Links
Contacts:
Media Relations Team
National Research Council of Canada
613-991-1431
1-855-282-1637 (24/7)
Twitter: (at)nrc_cnrc
Ilia A. Tikhomirov
President and CEO
AvidBiologics
647-255-1333
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2014 - 09:05 Uhr
Sprache: Deutsch
News-ID 1313360
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Anmerkungen:
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NRC and AvidBiologics Progress New Treatments to Seek and Destroy Cancer Cells
"
steht unter der journalistisch-redaktionellen Verantwortung von
National Research Council Canada-NRC and AvidBiologics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
